blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3717019

EP3717019 - RADIOPHARMACEUTICALS AND METHODS OF USE THEREOF [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  19.04.2024
Database last updated on 03.09.2024
FormerRequest for examination was made
Status updated on  04.09.2020
FormerThe international publication has been made
Status updated on  03.08.2019
Most recent event   Tooltip20.08.2024Change: Despatch of examination report + time limit 
Applicant(s)For all designated states
Board of Regents of the University of Nebraska
Verner Hall, 3835 Holdrege Street
Lincoln, Nebraska 68583-0745 / US
[2020/41]
Inventor(s)01 / GARRISON, Jered
1604 N. 154th Street
Omaha, NE 68154 / US
02 / FAN, Wei
10821 Western Plaza, Apt. 13
Omaha, NE 68154 / US
03 / ZHANG, Wenting
726 N. 91st Plaza, No. 4308
Omaha, NE 68114 / US
 [2020/41]
Representative(s)Potter Clarkson
Chapel Quarter
Mount Street
Nottingham NG1 6HQ / GB
[N/P]
Former [2020/41]Potter Clarkson
The Belgrave Centre
Talbot Street
Nottingham NG1 5GG / GB
Application number, filing date18902462.328.11.2018
[2020/41]
WO2018US62781
Priority number, dateUS201762591465P28.11.2017         Original published format: US 201762591465 P
[2020/41]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2019147338
Date:01.08.2019
Language:EN
[2019/31]
Type: A2 Application without search report 
No.:EP3717019
Date:07.10.2020
Language:EN
The application published by WIPO in one of the EPO official languages on 01.08.2019 takes the place of the publication of the European patent application.
[2020/41]
Search report(s)International search report - published on:US07.11.2019
(Supplementary) European search report - dispatched on:EP20.08.2021
ClassificationIPC:A61K51/08, A61K51/04, A61P35/00, C07K7/08
[2021/38]
CPC:
A61P35/00 (EP,US); A61K51/0497 (EP,US); A61K47/60 (US);
A61K47/65 (US); A61K51/08 (EP); A61K51/085 (EP,US);
C07K7/083 (EP,US); A61K38/00 (EP,US); A61K45/06 (US);
A61K9/0019 (US); C07K2319/035 (EP) (-)
Former IPC [2020/41]A61K47/64, A61K47/68
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/41]
TitleGerman:RADIOPHARMAZEUTIKA UND VERFAHREN ZUR VERWENDUNG DAVON[2020/41]
English:RADIOPHARMACEUTICALS AND METHODS OF USE THEREOF[2020/41]
French:PRODUITS RADIOPHARMACEUTIQUES ET LEURS PROCÉDÉS D'UTILISATION[2020/41]
Entry into regional phase26.06.2020National basic fee paid 
26.06.2020Search fee paid 
26.06.2020Designation fee(s) paid 
26.06.2020Examination fee paid 
Examination procedure26.06.2020Examination requested  [2020/41]
07.03.2022Amendment by applicant (claims and/or description)
23.04.2024Despatch of a communication from the examining division (Time limit: M06)
Fees paidRenewal fee
13.11.2020Renewal fee patent year 03
10.11.2021Renewal fee patent year 04
14.11.2022Renewal fee patent year 05
27.10.2023Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[A]US2010256055  (CASTAIGNE JEAN-PAUL [CA], et al) [A] 1-7 * entire document *;
 [A]US2014227175  (VASILJEVA OLGA [SI], et al) [A] 1-7* entire document *;
 [XY]WO2016077505  (AMUNIX OPERATING INC [US]) [X] 1, 2, 5, 6 * entire document * [Y] 3, 4, 7;
 [Y]US2017119913  (OSTERKAMP FRANK [DE], et al) [Y] 3, 4, 7 * entire document *;
 [A]US2017319643  (REMALEY ALAN T [US], et al) [A] 1-7 * entire document *;
 [PX]  - FAN et al., "Increasing time on target: utilization of inhibitors of cysteine cathepsins to enhance the tumor retention of receptor-targeted agents", Chemical Communications, (20181004), vol. 54, no. 80, doi:10.1039/C8CC05982A, pages 11268 - 11271, XP055650672 [PX] 1-7 * . entire document *

DOI:   http://dx.doi.org/10.1039/C8CC05982A
by applicantUS2010256055
 US2014227175
 WO2016077505
 US2017119913
 US2017319643
    - FANI et al., Theranostics, (20120000), vol. 2, page 481
    - FISCHMAN et al., J. Nucl. Med., (19930000), vol. 34, page 2253
    - OKARVI, S.M., Cancer Treat. Rev., (20080000), vol. 34, page 13
    - OGBOMO et al., Nucl. Med. Biol., (20130000), vol. 40, no. 5, pages 606 - 617
    - FAN et al., Mol. Pharm., (20170000), vol. 14, no. 5, pages 1405 - 1417
    - FAN et al., Biomaterials, (20160000), vol. 103, pages 101 - 115
    - SHI et al., Biomaterials, (20140000), vol. 35, no. 22, pages 5760 - 5770
    - FAN et al., Chem. Commun. (Camb., (20180000), vol. 54, no. 80, pages 11268 - 11271
    - HERMANS et al., Pharmacol. Ther., (19980000), vol. 79, page 89
    - MYERS et al., ACS Chem. Biol., (20090000), vol. 4, page 503
    - JIA et al., Nucl. Med. Biol., (20150000), vol. 42, page 816
    - XING et al., Biochem. J., (19980000), vol. 332, page 499
    - VERDOES, J. Am. Chem. Soc., (20130000), vol. 135, page 14726
    - CHOWDHURY et al., J. Med. Chem., (20140000), vol. 57, page 6092
    - HASHIDA et al., J. Biochem., (19820000), vol. 91, page 1373
    - SIKLOS et al., ActaPharm. Sin. B, (20150000), vol. 5, page 506
    - REISER, J. Clin. Invest., (20100000), vol. 120, page 3421
    - PALERMO et al., Trends Pharmacol. Sci., (20080000), vol. 29, page 22
    - TURK et al., Biochim. Biophys. Acta, (20120000), vol. 1824, page 68
    - JOYCE et al., Cell Cycle, (20040000), vol. 3, page 1516
    - AGGARWAL et al., Proteomics Clin. Appl., (20140000), vol. 8, page 427
    - KOS et al., Future Med. Chem., (20140000), vol. 6, page 1355
    - SUDHAN et al., Pharmacol. Ther., (20150000), vol. 155, page 105
    - SALPETER, Oncogene, (20150000), vol. 34, page 6066
    - KRANTZ et al., Biochemistry, (19910000), vol. 30, page 4678
    - WAGNER et al., J. Med. Chem., (19940000), vol. 37, page 1833
    - POWERS et al., Chem. Rev., (20020000), vol. 102, page 4639
    - OTTO, Chem. Rev., (19970000), vol. 97, page 133
    - OFORI et al., ACS Chem. Biol., (19770000), vol. 10, page 1977
    - JIA et al., Bioconjugate Chem., (20160000), vol. 27, page 2658
    - WU et al., Front. Endocrinol., (20120000), vol. 3, page 184
    - REUBI, J.C., Endocrine Reviews, (20030000), vol. 24, no. 4, pages 389 - 427
    - LACOEUILLE et al., Medecine Nucleaire, (20180000), vol. 42, pages 32 - 44
    - BROMME et al., J. Curr. Pharm. Des., (20020000), vol. 8, page 1639
    - RUKAMP et al., In Proteinase and Peptidase Inhibition: Recent Potential Targets for Drug Development, Taylor and Francis, (20020000), page 84
    - TOWATARI et al., FEBS Lett, (19910000), vol. 280, page 311
    - BLUM et al., Nat. Chem. Biol., (20070000), vol. 3, no. 668
    - VEGT et al., Eur. J. Nucl. Med. Mol. Imaging, (20110000), vol. 38, page 623
    - KATO et al., Nat. Chem. Biol., (20050000), vol. 1, page 33
    - DUMONT et al., J. Nucl. Med., (20130000), vol. 54, no. 5, pages 762 - 9
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.